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Figure 1. The linearity was analyzed by serially diluting (1:2, 1:4, 1:8, and
1:10)the mixed QC samples (MQC) and the unspiked pooled samples (P). The
observed concentration was plotted against the reciprocal of the dilution.
loss in the stability of the CTX II epitope out to 4 freeze/thaw
cycles. Differences in biological activity were identiﬁed when ex-
amining samples from 3 normal rested horses (111.40 ± 33.3
pg/ml), the same horses after 5 months race-training (158.18 ±
111 pg/ml), and those with naturally-occurring OC injuries (38.96
± 12.91 pg/ml) (Figure 2).
Figure 2. Differences in biological activity identiﬁed between samples from 3
horses before (Rested) and after 5 months race-training (Exercised) as well as
3 horses with OA. Signiﬁcant differences between groups are represented as
*P<0.05 using a Kruskal-Wallis test.
Conclusions: The Serum Pre-Clinical Cartilaps® ELISA is a
reproducible and valid assay for use with equine serum.
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Purpose: to evaluate the relationship between OPG and RANKL
in synovial ﬂuid and serum in patients with primary knee os-
teoarthritis and disease severity as it is graded radiologically
according to the system of Kallgren and Lawrence. To demon-
strate the role of the RANKL/OPG system in the pathophysiology
of primary knee osteoarthritis.
Methods: the study population included 37 patients (9 males,
28 females) with mean age 64.9 years (ranging from 50 to 80
years). Synovial ﬂuid was aspirated from the affected joint during
surgery where a total knee arthroplasty was performed. Blood
samples were obtained from the same patients 1 to 2 hours
before surgery. Anteroposterior weight bearing radiographs of
the patients’ knees were performed and osteoarthritic changes
were graded according to the system of Kallgren and Lawrence.
Results: we found that OPG concentration in synovial ﬂuid was
signiﬁcantly higher than in serum (257.5±76.9 vs 49.2±10.1
pmoles/lt, p<0,0001), indicating that the increase of OPG in
patients with knee OA is not systemic but rather localized in
the affected joint. OPG levels were increased in synovial ﬂuid
in relation with the severity of knee OA and were signiﬁcantly
higher in patients with OA grade 4 than in those with grade 1 or
2. RANKL levels were found low in both synovial ﬂuid and serum
(1.5±1.0 and 1.0±1.0 pmoles/lt respectively). Serum levels of
OPG and RANKL did not correlate with the severity of knee OA
Conclusions: based on the fact that OA is characterized by
progressive deterioration of the articular cartilage, the increase
of OPG in synovial ﬂuid of individuals with knee OA might
reﬂect a compensatory response by chondrocytes or synovial
ﬁbroblasts to destabilization of the coupling between degradation
and synthesis of articular cartilage. The increased concentration
of OPG might thus serve to protect cartilage rather than be a
cause of osteoarthritis.
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Purpose: Avocado and Soya (A/S 1:2 w/w) unsaponiﬁables
(ASU), developed and patented by Laboratoires Expanscience,
are the components of a medicinal product found in numerous
countries against degenerative osteoarthritis. The main ingredi-
ents are: 30% tocopherol, 25% sterols and 25% speciﬁc active
molecules. The originality is based on A/S ratio and Avocado
speciﬁc modiﬁed unsaponiﬁables obtained by chemical transfor-
mation of precursors. This modiﬁcation by hemisynthesis con-
stitutes one of the Laboratoires Expanscience know-how and is
patented.
In vitro published studies showed effects of ASU on the an-
abolism (increase in the synthesis of collagens, proteoglycans
and TGFβ) and catabolism (inhibition of synthesis of MMPs,
PGE2, and pro-inﬂammatory cytokines) of osteoarthritic chondro-
cytes. Moreover, clinical studies demonstrated the symptomatic
effect of ASU combined to a reduction in NSAID administration.
The pharmaceutical status requires perfect controls of the extrac-
tion process, of the hemisynthesis from precursors to converted
molecules and an excellent between-batch reproducibility.
This is ensured by a strict control of the whole plant process:
contractual partnerships with local subcontractors, expertise in
vegetable lipid chemistry allowing an exact deﬁnition of the plant
species extracted and the soils together with the application of
GMP rules for the whole process from the plant starting material
up to the pharmaceutical active ingredient.
Attracted by the scientiﬁc renown and success of pharmaceutical
ASU, nutraceutical companies have attempted to develop imita-
tions by suggesting more or less clearly a relation between the
composition and even the activity of the original pharmaceutical.
Methods: An analytical study of 7 nutraceutical products (for
human and veterinary uses) claiming the name ASU has been
performed by gas chromatography methodology.
Results: The analytical study of the nutraceutical products ver-
sus the original and authentic ASU showed:
– The complete absence of speciﬁc molecules which are
patented (obtained by transformation of avocado precursors)
evaluated by GC assay of silylderivatives on a 5%-phenyl-
methylpolysiloxane capillary column equipped with a cold on-
column injector and a FID detector;
– A content of unsaponiﬁables of less than 25% measured by a
method of the American Oil Chemistry Society N° Ca 6a-40;
– A lower sterol and tocopherol content of less than 15% and 5%
